Health Care Resource Use and Costs of Hemophilia B (HB) in French Adult Patients in 2022: A Nationwide Claims Database Analysis

Speaker(s)

Frenzel L1, Cahoreau V2, Giraud N3, Delienne S4, Fagnani F5, Bouee S6, Cottin J5, Bureau I5, Rudant J7, Reynaud A7, Fahfouhi Y7, Martin L7, Beillat M7, Kachaner I7, Lilliu H8, Lebreton A9
1Hôpital Necker, Paris, France, 2CHU Bordeaux, Bordeaux cedex, France, 3Association Française des Hémophiles, Paris, France, 4CHU Dijon, Dijon cedex, France, 5CEMKA, Bourg-la-Reine, France, 6CEMKA, BOURG LA REINE, France, 7Pfizer, Paris, France, 8Inbeeo, London, LON, UK, 9CHU Clermont-Ferrand, Clermont-Ferrand, France

Presentation Documents

OBJECTIVES: There are few data on healthcare resource use and related costs of French HB patients. The aim of this study was to describe these features in French adult HB patients according to severity in 2022.

METHODS: Data related to adult HB patients alive on 1/1/2022 were extracted from the French claims database (SNDS). A control group without HB matched on age, gender and region was randomly selected in the database. Sub-group analyses were performed according to the treatment regimen (on demand or prophylaxis) and the presence of inhibitors. Direct costs were estimated in a societal perspective.

RESULTS: 1,022 adult patients with HB were identified. Mean age was 45 years, 81.2% were males.

Among the patient’s population, 78.2%, 0.6%, 20.9% and 0.3% patients were treated on demand without and with inhibitors and in prophylaxis without and with inhibitors, respectively.

Compared to controls, patients with HB had more frequently consultations with general practitioners (79.8%/66.1%), hospital specialists (58.5%/25.9%), nurses (69.1%/42.7%), physiotherapists (22.2%/13.6%) and visits to emergency room visits (26.4%/15.9%). They were more frequently treated with analgesics (93.2%/81.5%) and corticosteroids (51.8%/44.7%) but less frequently with non-steroid anti-inflammatory drugs (52.4%/63.65%). The proportion of HB patients hospitalized was higher than controls, overall (26.7% vs 12.8%) and for bleeding (1.7% vs 0.2%) and orthopedic surgery (8.3% vs 5.7%).

The mean annual direct medical costs varied according to treatment patterns:

  • €7,128 for patients treated on demand without inhibitors (€1,907 for controls)
  • €199,792 for patients treated in prophylaxis without inhibitors (€1,428 for controls)
The majority of the costs was related to antihemophilic drugs: 47% and 95% respectively for the 2 treatment groups.

CONCLUSIONS: The cost of HB is high, varies greatly with treatment regimen and presence of inhibitors, and is mostly due to the antihemophilic drugs.

Code

EE156

Topic

Economic Evaluation, Epidemiology & Public Health, Study Approaches

Disease

Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)